For the year ending 2025-12-31, RXRX made $74,681K in revenue. -$644,759K in net income. Net profit margin of -863.35%.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total revenue | 74,681 | 58,839 | 44,575 | 39,843 |
| Cost of revenue | 70,953 | 45,238 | 42,587 | 48,275 |
| Research and development | 475,271 | 314,421 | 241,226 | 155,696 |
| General and administrative | 176,589 | 178,184 | 110,822 | 81,599 |
| Total operating costs and expenses | 722,813 | 537,843 | 394,635 | 285,570 |
| Loss from operations | -648,132 | -479,004 | -350,060 | -245,727 |
| Other income, net | 3,237 | 14,216 | 17,932 | 6,251 |
| Loss before income tax benefit | -644,895 | -464,788 | -332,128 | - |
| Income tax benefit | -136 | -1,127 | -4,062 | - |
| Net loss | -644,759 | -463,661 | -328,066 | -239,476 |
| Basic EPS | -1.44 | -1.69 | -1.58 | -1.36 |
| Diluted EPS | -1.44 | -1.69 | -1.58 | -1.36 |
| Basic Average Shares | 447,446,109 | 274,207,146 | 207,853,702 | 175,537,487 |
| Diluted Average Shares | 447,446,109 | 274,207,146 | 207,853,702 | 175,537,487 |
RECURSION PHARMACEUTICALS, INC. (RXRX)
RECURSION PHARMACEUTICALS, INC. (RXRX)